Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
81.07
+1.58 (+1.99%)
4:59:54 PM EDT: $81.10 +0.03 (+0.04%)
Products

FDA Grants Priority Review To Merck’S Supplemental Biologics License Application For Keytruda® (Pembrolizumab)

Published: 12/17/2020 11:56 GMT
Merck & Co Inc (MRK) - FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda® (pembrolizumab) Plus Chemotherapy As First-line Treatment for Locally Advanced Unresectable Or Metastatic Esophageal and Gastroesophageal Junction Cancer.
Merck & Co Inc - FDA Has Set PDUFA Or Target Action, Date of April 13, 2021.